skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2
Patent #:
Issue Dt:
01/02/2018
Application #:
15215909
Filing Dt:
07/21/2016
Publication #:
Pub Dt:
11/10/2016
Inventors:
Ki Yean NAM, Jeong Jun KIM, Sae Yeon LEE, Ji Ye AHN, Jaeseung KIM, Chunwon JUNG et al
Title:
TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION WITH ZILEUTON CREAM FORMULATION
Assignment: 1
Reel/Frame:
040328/0589Recorded: 11/15/2016Pages: 11
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Assignee:
C-DONG, 8TH FLOOR, PANGYO-RO 242, BUNDANG-GU
SEONGNAM-SI, GYEONGGI-DO, CHINA 463-400
Correspondent:
DAVID R. SALIWANCHIK
P.O. BOX 142950
GAINESVILLE, FL 32614-2950
Assignment: 2
Reel/Frame:
040796/0904Recorded: 12/02/2016Pages: 13
Conveyance:
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 040328 FRAME 0589. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST.
Assignors:
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Exec Dt:
10/04/2016
Assignee:
C-DONG, 8TH FLOOR, PANGYO-RO 242, BUNDANG-GU
SEONGNAM-SI, GYEONGGI-DO, KOREA, REPUBLIC OF 463-400
Correspondent:
DAVID R. SALIWANCHIK
P.O. BOX 142950
GAINESVILLE, FL 32614-2950

Search Results as of: 06/22/2024 06:32 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT